Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.

Abstract

Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-derived endothelial cell growth factor (PD-ECGF). We conducted immunohistochemical staining of dThdPase to assess correlation between its expression in cancer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherapy and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor and stromal cells. Survival curves significantly differed between stromal dThdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining success of the combination therapy.

Statistics

0500100020072008200920102011201220132014201520162017
Citations per Year

685 Citations

Semantic Scholar estimates that this publication has 685 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Sato2001PrognosticVO, title={Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.}, author={Shin Sato and Aiji Yajima and Hideo Sasaki and Kenmei Mizutani and Hideo Honjo and Kei Yamamoto and Moeko Ozaki and Kiyoshi Hasegawa and Takafumi Kudo and Michiaki Yakushiji and Masayuki Hatae and Kiichiro Noda}, journal={Oncology reports}, year={2001}, volume={8 2}, pages={239-44} }